Incyte's Minjuvi gains Japan approval with 71.4% response
Incyte (NASDAQ:INCY) received Japanese regulatory approval for its cancer drug Minjuvi after clinical trials demonstrated response rates up to 71.4%.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Incyte (NASDAQ:INCY) received Japanese regulatory approval for its cancer drug Minjuvi after clinical trials demonstrated response rates up to 71.4%.
Ethereum (CRYPTO:ETH) could face a funding gap for core protocol development within the next three to nine months.
Bitcoin (CRYPTO:BTC) has rebounded from a June selloff but remains about 15% below Glassnode’s True Market Mean of US$77,200.
Senator Bill Hagerty said he remains hopeful that lawmakers can advance the Digital Asset Market Clarity Act before Congress breaks for the July 4 recess.
Capital B approved shareholder resolutions authorising up to €105 billion in financing capacity to fund additional Bitcoin (CRYPTO:BTC) purchases and expand its treasury strategy.
IDP Education (ASX:IEL) announced an on-market share buy-back programme of up to $50 million and updated its financial expectations.
HIVE Digital Technologies signed a US$220 million, three-year GPU cloud contract with Bell Canada and Cohere.
BHP (ASX:BHP) confirmed that total cost blowouts for the first two stages of its Jansen Potash Project have risen to US$4.7 billion
Apple (NASDAQ:AAPL) will allow Brazilian developers to distribute software and process payments outside its official marketplace in iOS 26.5.
Kraken has launched on-chain decentralised exchange trading inside its main app, giving users direct access to a wider range of Solana ecosystem tokens.